Lumentum to Participate in Upcoming Investor Events
Get Alerts LITE Hot Sheet
Join SI Premium – FREE
SAN JOSE, Calif., Feb. 26, 2020 /PRNewswire/ -- Lumentum Holdings Inc. ("Lumentum") today announced that management is scheduled to participate in the following investor conferences:
Event: | Raymond James 41st Annual Institutional Investors Conference |
Date: | Monday, March 2, 2020 |
Location: | JW Marriott Grande Lakes – Orlando |
Presentation Time: | 2:15 p.m. Eastern Time |
Event: | Morgan Stanley Technology, Media & Telecom Conference |
Date: | Wednesday, March 4, 2020 |
Location: | The Palace Hotel – San Francisco |
Presentation Time: | 4:45 p.m. Pacific Time |
A webcast of the presentation, when available, will be accessible in the investor relations section of the Company's website at http://investor.lumentum.com.
About Lumentum
Lumentum (NASDAQ: LITE) is a market-leading designer and manufacturer of innovative optical and photonic products enabling optical networking and laser applications worldwide. Lumentum's optical components and subsystems are part of virtually every type of telecom, enterprise, and data center network. Lumentum's lasers enable advanced manufacturing techniques and diverse applications including next-generation 3D sensing capabilities. Lumentum is headquartered in San Jose, California with R&D, manufacturing, and sales offices worldwide. For more information, visit www.lumentum.com.
Contact | |
Investors: | Jim Fanucchi, 408-404-5400; [email protected] |
Media: | Sean Ogarrio, 408-546-5405; [email protected] |
View original content:http://www.prnewswire.com/news-releases/lumentum-to-participate-in-upcoming-investor-events-301011265.html
SOURCE Lumentum
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Red Bull Athlete Thomas van Tonder Crosses 600 Monkey Bars Under Bloukrans Bridge
- New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA
- Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Raymond James, Morgan StanleySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share